Trial Profile
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Budesonide; Colestipol; Loperamide
- Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational
- Acronyms CONTROL
- Sponsors Puma Biotechnology
- 10 Dec 2021 According to a Pierre Fabre media release, this study final results were submitted to the European Medicines Agency in order to align the Product Information with the current scientific knowledge.
- 10 Dec 2021 According to a Pierre Fabre media release, data were presented at the 2021 San Antonio Breast Cancer Symposium (SABCS).
- 10 Dec 2021 Results presented in a Pierre Fabre Media Release.